From the Guidelines
Mydayis is a suitable treatment option for attention-deficit/hyperactivity disorder (ADHD) in patients 13 years and older, with a recommended starting dose of 12.5 mg once daily in the morning, adjustable up to 25 mg daily for adolescents or 50 mg daily for adults, based on response and tolerability, as supported by recent evidence 1.
Key Considerations
- Mydayis contains mixed amphetamine salts (dextroamphetamine and amphetamine) in an extended-release formulation, providing symptom control for up to 16 hours.
- The medication works by increasing levels of neurotransmitters like dopamine and norepinephrine in the brain, improving attention, focus, and impulse control.
- Common side effects include decreased appetite, insomnia, dry mouth, and increased heart rate, with risks of misuse and dependence, classified as a Schedule II controlled substance.
Monitoring and Follow-up
- Patients should take Mydayis exactly as prescribed, avoiding afternoon dosing to prevent sleep difficulties.
- Regular follow-up appointments are necessary to monitor effectiveness and side effects, with particular attention to pulse, blood pressure, height, and weight, as stimulant medications can have statistically significant effects on these parameters 1.
Treatment Approach
- The choice of medication should consider individual patient factors, such as severity of symptoms, presence of comorbidities, and patient preferences, as a "one-size-fits-all" approach is not adequate for ADHD treatment 1.
- Stimulants, including Mydayis, are generally recommended as first-line therapy, with non-stimulants as second-line options, although approval statuses may vary between countries 1.
From the Research
Mydayis
- Mydayis is a medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) [@\5@]
Mechanism of Action
- Mydayis is a combination of methylphenidate and other compounds, which work by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine [@\1@, @\2@]
Efficacy
- Studies have shown that methylphenidate, a key component of Mydayis, is effective in reducing ADHD symptoms in children and adolescents [@\3@, @\4@]
- A systematic review of 16 randomized clinical trials found that extended-release methylphenidate improved ADHD symptoms in adolescents [@\3@]
- Another systematic review of 212 trials found that methylphenidate improved teacher-rated ADHD symptoms in children and adolescents [@\4@]
Safety
- Common side effects of methylphenidate include irritability, appetite reduction, palpitations, and headache [@\1@]
- A systematic review found that methylphenidate was associated with an increased risk of adverse events considered non-serious, such as sleep problems and decreased appetite [@\4@]
Comparison to Other Medications
- Amfetamine and methylphenidate medications have been found to be complementary treatment options for ADHD [@\5@]
- A review of published clinical studies found that both methylphenidate- and amfetamine-based stimulants had robust efficacy and acceptable safety outcomes in children and adolescents with ADHD [@\5@]